Bayer is the pharmaceuticals company most prolific at making international expansions, followed by Novartis and AstraZeneca. GlobalData’s pharmaceuticals foreign direct investment (FDI) company report highlights the current foreign investments made by leading pharmaceuticals investors. Buy the report here.
Bayer has been the most active pharmaceuticals greenfield investor between Q1 2019 and Q3 2023, according to GlobalData’s FDI Projects Database.
Greenfield foreign direct investment is when a company invests abroad to establish a new physical presence or expand an existing operation. Greenfield investments create jobs and/or involve a capital investment into the foreign location. Other forms of FDI, such as mergers and acquisitions, are not included as part of this definition.
The majority of Bayer investments were in the drug manufacturers subsector. In fact, 71.2% of its total foreign investments were in this subsector. It also created projects across a further 8 subsectors.
The company has been active across eight world regions, mainly focused on Asia which received 27.1% of the company’s greenfield investments between Q1 2019 and Q3 2023. Its top three destination countries (by number of greenfield FDI projects) were India, the US and Spain. Combined these three countries account for 61.9% of its total number of pharmaceuticals investments.
Bayer created more FDI projects in 2022 compared to any other year between Q1 2019 and Q3 2023.
The US is the leading source market for outbound pharmaceuticals greenfield FDI projects. The country accounts for 25.4% of total outbound pharmaceuticals investment projects. There have been 144 unique parent companies from the US that have announced pharmaceuticals FDI projects between between Q1 2019 and Q3 2023.
To further understand the top pharmaceuticals FDI companies, access GlobalData’s Top Pharmaceuticals Foreign Direct Investment Companies report.